ChemoMetec A/S (FRA:CHY)

ChemoMetec Statistics

Total Valuation

ChemoMetec has a market cap or net worth of EUR 931.73 million. The enterprise value is 895.67 million.

Market Cap	931.73M
Enterprise Value	895.67M

Important Dates

The last earnings date was Wednesday, February 4, 2026.

Earnings Date	Feb 4, 2026
Ex-Dividend Date	Oct 10, 2025

Share Statistics

Current Share Class	17.40M
Shares Outstanding	n/a
Shares Change (YoY)	+0.07%
Shares Change (QoQ)	-0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	16.75M

Valuation Ratios

The trailing PE ratio is 39.31 and the forward PE ratio is 28.02.

PE Ratio	39.31
Forward PE	28.02
PS Ratio	14.11
PB Ratio	10.66
P/TBV Ratio	14.36
P/FCF Ratio	38.83
P/OCF Ratio	33.12
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 27.41, with an EV/FCF ratio of 37.32.

EV / Earnings	37.79
EV / Sales	13.57
EV / EBITDA	27.41
EV / EBIT	28.96
EV / FCF	37.32

Financial Position

The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.01.

Current Ratio	3.93
Quick Ratio	3.02
Debt / Equity	0.01
Debt / EBITDA	0.02
Debt / FCF	0.03
Interest Coverage	172.83

Financial Efficiency

Return on equity (ROE) is 28.31% and return on invested capital (ROIC) is 46.70%.

Return on Equity (ROE)	28.31%
Return on Assets (ROA)	19.08%
Return on Invested Capital (ROIC)	46.70%
Return on Capital Employed (ROCE)	35.01%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	383,874
Profits Per Employee	137,810
Employee Count	172
Asset Turnover	0.65
Inventory Turnover	0.18

Taxes

In the past 12 months, ChemoMetec has paid 6.91 million in taxes.

Income Tax	6.91M
Effective Tax Rate	22.58%

Stock Price Statistics

The stock price has decreased by -32.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-32.55%
50-Day Moving Average	82.39
200-Day Moving Average	80.39
Relative Strength Index (RSI)	17.61
Average Volume (20 Days)	17

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ChemoMetec had revenue of EUR 66.03 million and earned 23.70 million in profits. Earnings per share was 1.36.

Revenue	66.03M
Gross Profit	63.08M
Operating Income	30.94M
Pretax Income	30.62M
Net Income	23.70M
EBITDA	32.69M
EBIT	30.94M
Earnings Per Share (EPS)	1.36

Balance Sheet

The company has 36.78 million in cash and 697,735 in debt, with a net cash position of 36.08 million.

Cash & Cash Equivalents	36.78M
Total Debt	697,735
Net Cash	36.08M
Net Cash Per Share	n/a
Equity (Book Value)	87.38M
Book Value Per Share	5.02
Working Capital	48.36M

Cash Flow

In the last 12 months, operating cash flow was 28.13 million and capital expenditures -4.13 million, giving a free cash flow of 24.00 million.

Operating Cash Flow	28.13M
Capital Expenditures	-4.13M
Free Cash Flow	24.00M
FCF Per Share	n/a

Margins

Gross margin is 95.54%, with operating and profit margins of 46.86% and 35.90%.

Gross Margin	95.54%
Operating Margin	46.86%
Pretax Margin	46.37%
Profit Margin	35.90%
EBITDA Margin	49.51%
EBIT Margin	46.86%
FCF Margin	36.35%

Dividends & Yields

This stock pays an annual dividend of 0.94, which amounts to a dividend yield of 1.71%.

Dividend Per Share	0.94
Dividend Yield	1.71%
Dividend Growth (YoY)	74.73%
Years of Dividend Growth	1
Payout Ratio	68.81%
Buyback Yield	-0.07%
Shareholder Yield	1.64%
Earnings Yield	2.54%
FCF Yield	2.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ChemoMetec has an Altman Z-Score of 49.32 and a Piotroski F-Score of 6.

Altman Z-Score	49.32
Piotroski F-Score	6